A pilot open-label trial of zonisamide in Unverricht-Lundborg disease

Movement Disorders

Volumn 26, Issue 2, 2011, Pages 341-343

  Italiano, Domenico ^a   Pezzella, Marianna ^b   Coppola, Antonietta ^c   Magaudda, Adriana ^d   Ferlazzo, Edoardo ^a   Bramanti, Placido ^a   Striano, Salvatore ^c   Zara, Federico ^b   Striano, Pasquale ^b  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Epilepsy; Myoclonus; Unverricht Lundborg disease; Zonisamide

Indexed keywords

ACETAZOLAMIDE; CLONAZEPAM; ETIRACETAM; PHENOBARBITAL; PRIMIDONE; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IRRITABILITY; MALE; MYOCLONUS EPILEPSY; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; UNIFIED MYOCLONUS RATING SCALE;

ADULT; AGED; ANTICONVULSANTS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MYOCLONUS; PILOT PROJECTS; TREATMENT OUTCOME; UNVERRICHT-LUNDBORG SYNDROME;

EID: 79952670916     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23392     Document Type: Article

References (10)

1. Andrade DM, Hamani C, Minassian BA. Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus. Expert Opin Pharmacother 2009; 10: 1549-1560.
2. Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 2006; 47: 860-866.
3. Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007; 75: 75-83.
4. Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988; 38: 928-931.
5. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998; 29: 109-114.
6. Vossler DG, Conry JA, Murphy JV. ZNS-502/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008; 10: 31-34.
7. Frucht SJ, Leurgans SE, Hallett M, Fahn S. The unified myoclonus rating scale. Adv Neurol 2002; 89: 361-376.
8. Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004; 45: 678-681.
9. Aykutlu E, Baykan B, Gürses C, Bebek N, Büyükbabani N, Gökyigit A. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav 2005; 6: 260-263.
10. Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 2006; 47: 2083-2085.